Regulation of Medical Devices Regulation of Medical Devices Celia M. Witten, Ph.D., M.D. Celia M. Witten, Ph.D., M.D. Director Director Division of General, Restorative Division of General, Restorative and and Neurological Devices Neurological Devices Office of Device Evaluation Office of Device Evaluation Food and Drug Administration Food and Drug Administration RHAIR RHAIR Society for Academic Emergency Society for Academic Emergency Medicine Medicine Boston, Massachusetts Boston, Massachusetts May 31, 2003 May 31, 2003
27
Embed
Regulation of Medical Devices Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Regulation of Medical DevicesRegulation of Medical DevicesCelia M. Witten, Ph.D., M.D.Celia M. Witten, Ph.D., M.D.
DirectorDirectorDivision of General, Restorative Division of General, Restorative
andandNeurological DevicesNeurological Devices
Office of Device EvaluationOffice of Device EvaluationFood and Drug AdministrationFood and Drug Administration
RHAIRRHAIR
Society for Academic Emergency Society for Academic Emergency MedicineMedicine
Boston, MassachusettsBoston, Massachusetts
May 31, 2003May 31, 2003
22
OutlineOutline
Who we areWho we are Device typesDevice types Paths to marketPaths to market Temperature control devicesTemperature control devices Clinical study regulationClinical study regulation
marketed, not subject to PMA)marketed, not subject to PMA) ComparisonComparison
– same intended use andsame intended use and– same technological characteristics orsame technological characteristics or– different technological characteristics different technological characteristics
andand– as safe and effective as predicateas safe and effective as predicate
Presents a potential serious risk to Presents a potential serious risk to the health, safety, and welfare of a the health, safety, and welfare of a subject and is:subject and is:– an implant; oran implant; or– life supporting or sustaining; orlife supporting or sustaining; or– of substantial importance in of substantial importance in
diagnosing, curing, mitigating, or diagnosing, curing, mitigating, or treating disease or preventing treating disease or preventing impairment of human healthimpairment of human health
NSR devices can be SR studiesNSR devices can be SR studies
1717
Informed Consent: Informed Consent: Emergency UseEmergency Use
Must be reviewed and Must be reviewed and approved by the IRB and the approved by the IRB and the FDA prior to useFDA prior to use
May be waived when there is May be waived when there is a life-threatening situationa life-threatening situation– the subject cannot communicatethe subject cannot communicate– time is not sufficienttime is not sufficient– no available alternativeno available alternative– two physicians certify in writing two physicians certify in writing
1818
Informed Consent: Informed Consent: Emergency ResearchEmergency Research
Certain studies may not require Certain studies may not require informed consent when IRB agrees informed consent when IRB agrees thatthat– there is a life-threatening situation and there is a life-threatening situation and
currentcurrent
treatments are unsatisfactorytreatments are unsatisfactory– no timeno time– can’t identify subjects prospectively can’t identify subjects prospectively – community consultationcommunity consultation– public disclosurepublic disclosure
1919
When Are Clinical Data When Are Clinical Data Needed?Needed?
To support:To support: PMA, PDP or HDE (almost always)PMA, PDP or HDE (almost always) 510(k) (<10%)510(k) (<10%) New indication for an New indication for an approvedapproved
device (e.g., BPH for a urologic device (e.g., BPH for a urologic laser)laser)
Significant change to device, Significant change to device, especially Class III devicesespecially Class III devices
– FeasibilityFeasibility– Pivotal, including sites outside Pivotal, including sites outside
the USthe US– Post-approvalPost-approval
2121
Feasibility TrialFeasibility Trial
Answer design-related questions Answer design-related questions that cannot be addressed by that cannot be addressed by bench/animal testingbench/animal testing
Modify device design &/or Modify device design &/or instructions for useinstructions for use
Preliminary safety dataPreliminary safety data No controlNo control Limited # pts/limited follow-upLimited # pts/limited follow-up
2222
Pivotal TrialPivotal Trial
Final design, indication for use, Final design, indication for use, and protocoland protocol
ControlledControlled Masked, if possibleMasked, if possible Primary/secondary endpointsPrimary/secondary endpoints Develop information for labelingDevelop information for labeling Statistical validity to show S & EStatistical validity to show S & E
2323
Post-ApprovalPost-Approval
May be required for PMA May be required for PMA approvalapproval
Designed to address specific Designed to address specific questionquestion
# of patients and duration # of patients and duration specified by FDAspecified by FDA
2424
Cooling Devices:Cooling Devices:Clinical Study Clinical Study
QuestionsQuestions How soon?How soon? How cold?How cold? How fast?How fast? How long?How long? How measured?How measured? Speed of rewarming?Speed of rewarming? Other treatments provided?Other treatments provided? Local versus systemic?Local versus systemic?
2525
Temperature Control Temperature Control DevicesDevices
Tool?Tool? Treatment?Treatment?
2626
Temperature Control Temperature Control DevicesDevices